Turkish Journal of Hematology Volume: 37 Issue: 1 / 2020

More documents

Recommendations

Info

Ardıçoğlu Akışın Y and Akar N: Platelet Satellitism Turk J Hematol 2020;37:55-56Authorship ContributionsDrafting, reviewing: Y.A.A.; Reviewing: Y.A.A., N.A.Conflict of Interest: The authors declare that there is no conflictof interest.Financial Disclosure: The authors have no sources of support forthis work.References1. Bizzaro N, Goldschmeding R, von dem Borne AE. Platelet satellitism is Fcgamma RIII (CD16) receptor-mediated. Am J Clin Pathol 1995;103:740-744.2. Bobba RK, Doll DC. Platelet satellitism as a cause of spuriousthrombocytopenia. Blood 2012;119:4100.3. LabCE. Pseudo-thrombocytopenia: Platelet Satellitism and PlateletClumping. LabCE, 2019. Available online at https://www.labce.com/spg280957_pseudo_thrombocytopenia_platelet_satellitism_and_p.aspx4. Chakrabart I. Platelet satellitism: a rare, interesting, in vitro phenomenon.Indian J Hematol Blood Transfus 2014;30:213-214.56
LETTERS TO THE EDITORTurk J Hematol 2020;37:57-76Assessment of Patients with von Willebrand Disease with ISTH/BAT and PBQ ScoresVon Willebrand Hastalığı Olgularının ISTH/BAT ve PBQ Skorları ile DeğerlendirilmesiFatma Burcu Belen Apak 1 , Elif Gülsüm Ümit 2 , Yağmur Zengin 3 , Melike Sezgin Evim 4 , Ekrem Ünal 5 , Hasan Mücahit Özbaş 6 ,Can Acıpayam 71Başkent University Faculty of Medicine, Department of Pediatric Hematology Oncology, Ankara, Turkey2Trakya University Faculty of Medicine, Department of Hematology, Edirne, Turkey3Başkent University Faculty of Medicine, Department of Biostatistics, Ankara, Turkey4Uludağ University Faculty of Medicine, Department of Pediatric Hematology Oncology, Bursa, Turkey5Erciyes University Faculty of Medicine, Department of Pediatric Hematology Oncology, Kayseri, Turkey6Giresun University Faculty of Medicine, Department of Hematology, Giresun, Turkey7Kahramanmaraş Sütçü İmam University Faculty of Medicine, Department of Pediatric Hematology and Oncology, Kahramanmaraş, TurkeyTo the Editor,The Turkish Society of Hematology initiated the TurkishHemophilia Masterclass Academy program in 2016 to encourageyoung hematologists entering the field of hemophilia. Theprogram involved 6 months of training, supported by monthlyexams. We, as a group of mentees from the HemophiliaMasterclass Academy, aimed to evaluate the bleedingphenotype of patients with von Willebrand Disease (VWD)using the International Society of Thrombosis and Haemostasis-Bleeding Assessment Tool (ISTH-BAT) and the Pediatric BleedingQuestionnaire (PBQ) scores and investigate the correlation ofvon Willebrand factor antigen (VWF:Ag) levels and bleedingscores of the patients, as well as present the initial output ofour Masterclass Academy.The study included 62 patients (aged 3-61 years) with thediagnosis of VWD (54 patients with VWD type 1 and 8 withVWD type 3). The ISTH-BAT and PBQ were administered topatients who were ≥18 years old and <18 years old, respectively.Informed consent was obtained from all patients.The VWF:Ag levels, ristocetin cofactor activity (VWF:Ricof), andFVIII levels were retrospectively reviewed from the patient records.The cut-off point for a positive score was accepted as ≥2 for thePBQ and ≥3 for the ISTH-BAT. Statistical analysis was performedusing SPSS 17.0. Demographic findings, median bleeding scores,and VWF levels are presented in Table 1. Epistaxis, superficialbleedings, bleeding from minor wounds, oral bleeding, umbilicalbleeding, and muscle hematoma were found to be statisticallysignificant in showing dependence between the diagnosticstatus and the bleeding symptoms (p<0.05). The study aimed toinvestigate the correlation between the VWF:Ag levels and thebleeding scores in our patients. Our study showed that VWF:Aglevels were inversely correlated with the bleeding scores of thepatients (Table 2).The evaluation of bleeding scores dates back to the Vicenzascore that was used in VWD patients [1,2,3]. In 2009, Bowmanet al. [4] published the PBQ, and it was investigated in ourpopulation with VWD previously [5]. In 2010, the ISTH-BATscore was established by the ISTH/SSC Joint Working Group[6,7]. One of the limitations of our study was the use of the PBQin children and ISTH-BAT in adults, which might have causedheterogeneity in the evaluation of the scores. Moreover, thelack of a control group, consisting of patients who had bleedingsymptoms but were normal by hemostatic tests, left us unableto compare the VWD patients and normal individuals. Althoughthe median total scores of the types 1 and 3 VWD groups werecompatible with previous studies, the positive scores reportedin each subgroup for epistaxis, oral cavity bleeding, cutaneousbleeding, and bleeding after minor wounds were found toTable 1. Characteristics of von Willebrand type 1 and type 3patients.VWD type 1(n=54)VWD type 3(n=8)Median age, years (minimum-maximum) 28 (3-61) 17 (6-30)Pediatric/Adult 13/41 3/5Female 46 6Male 8 2VWF:Ag (IU/dL) 22.23 (2-50) 2.5 (0-10)VWF:Ricof (IU/dL) 23.3 (8.3-45) 7.5 (6-23)FVIII (IU/dL) 45 (15-70) 3 (1-11.5)Median total score (minimum-maximum) 3 (0-19) 16 (9-27)VWF:Ag: von Willebrand factor antigen level, VWF:Ricoll: von Willebrand Factorristocetin cofactor level, VWD: von Willebrand disease.57
Page 1:
Volume 37 Issue 1March 2020E-ISSN:
Page 4 and 5:
Contact InformationEditorial Corres
Page 6 and 7:
TURKISH JOURNAL OF HEMATOLOGYINSTRU
Page 8 and 9:
published research articles on the
Page 10 and 11:
e-mail address. The system will sen
Page 12 and 13:
59 Children with Iron Deficiency An
Page 14 and 15:
Aladağ E, et al: Acute Graft-Versu
Page 16 and 17:
Aladağ E, et al: Acute Graft-Versu
Page 18 and 19: Koca D, et al: Therapeutic Potentia
Page 26 and 27: Li SJ, et al: The Efficacy and Safe
Page 32 and 33: RESEARCH ARTICLEDOI: 10.4274/tjh.ga
Page 34 and 35: Matsumura A, et al: ST2 for Transpl
Page 44 and 45: Niazkar HR, et al: First-time Blood
Page 46 and 47: Niazkar HR, et al: First-time Blood
Page 50 and 51: Gonzalez-Mancera MS, et al: Double-
Page 52 and 53: Gonzalez-Mancera MS, et al: Double-
Page 54 and 55: PERSPECTIVES IN HEMATOLOGYDOI: 10.4
Page 56 and 57: Haznedaroğlu İC, et al: Tyrosine
Page 58 and 59: Haznedaroğlu İC, et al: Tyrosine
Page 60 and 61: BRIEF REPORTDOI: 10.4274/tjh.galeno
Page 62 and 63: Demiröz AS, et al: Blastic Plasmac
Page 64 and 65: Demiröz AS, et al: Blastic Plasmac
Page 66 and 67: Pantelic M, et al: Kasabach-Merritt
Page 70 and 71: LETTERS TO THE EDITOR Turk J Hemato
Page 72 and 73: LETTERS TO THE EDITORTurk J Hematol
Page 88: LETTERS TO THE EDITORTurk J Hematol
show all

Turkish Journal of Hematology Volume: 37 Issue: 1 / 2020

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?